Pittsburgh Compound B

N/A

Report date: 2022/08/29 20:00:24

Base Information

Drug NamePittsburgh Compound B
Drug Alias Name[11C]Pittsburgh Compound B[11C]6-OH-BTA-111C-PIB[11C]PIB
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBeta amyloid A4 protein inhibitors
TargetsBeta amyloid A4 protein
Therapy Area/IndicationsAlcoholismAlzheimer DiseaseDementia +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesThe University Of UtahUniversity Of PittsburghGe Healthcare +[4] 
China Registration ClassN/A

Develop Information

Active CompaniesVanderbilt University Medical CenterUniversity Of North Carolina At Chapel HillUniversity Of Alabama At Birmingham
Inactive CompaniesJohns Hopkins UniversityUniversity Of PittsburghNational Institute Of Mental Health (Nimh)
Active IndicationsAlzheimer DiseaseBrain ConcussionParkinson Disease
Inactive IndicationsAlcoholismDementiaOvarian Neoplasms +[4] 

Other Information

ATC CodeN/A
Related LinksWikipedia